​

Twist Bioscience (TWST) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TWST Stock Forecast

Twist Bioscience (TWST) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $153.70, with a high of $215.00 and a low of $89.00. This represents a 9.85% increase from the last price of $139.92.

- $50 $100 $150 $200 $250 High: $215 Avg: $153.7 Low: $89 Last Closed Price: $139.92

TWST Stock Rating

Twist Bioscience stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (73.33%), 2 Hold (13.33%), 2 Sell (13.33%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 2 2 11 Strong Sell Sell Hold Buy Strong Buy

TWST Price Target Upside V Benchmarks

TypeNameUpside
StockTwist Bioscience9.85%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5929
Avg Price Target$194.40$167.33$103.17
Last Closing Price$139.92$139.92$139.92
Upside/Downside38.94%19.59%-26.27%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 262731-13
Sep, 26272--11
Aug, 26272--11
Jul, 26281--11
Jun, 26181--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 12, 2026Canaccord Genuity$205.00$159.7828.30%46.51%
Oct 08, 2026Matthew StantonJefferies$150.00$155.65-3.63%7.20%
Oct 07, 2026Barclays$215.00$166.9728.77%53.66%
Oct 01, 2026Guggenheim$212.00$197.207.51%51.52%
Sep 29, 2026Puneet SoudaLeerink Partners$190.00$182.094.34%35.79%
Sep 17, 2026Puneet SoudaLeerink Partners$160.00$143.0711.83%14.35%
Sep 09, 2026UBS$144.00$128.0612.45%2.92%
Aug 05, 2026Piper Sandler$115.00$99.4515.64%-17.81%
Aug 04, 2026Robert W. Baird$115.00$101.0613.79%-17.81%
Jul 16, 2026Puneet SoudaLeerink Partners$110.00$92.6118.78%-21.38%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 13, 2026Cowen & Co.BuyBuyhold
Oct 08, 2026JefferiesHoldinitialise
Oct 07, 2026BarclaysOverweightOverweighthold
Oct 01, 2026GuggenheimBuyBuyhold
Sep 09, 2026BWS FinancialSellinitialise
Sep 09, 2026UBSNeutralinitialise
Aug 24, 2026GuggenheimBuyBuyhold
Aug 05, 2026Piper SandlerOverweightOverweighthold
Aug 03, 2026Cowen & Co.BuyBuyhold
Jun 29, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-4.04$-3.60$-3.60$-1.30----
Avg Forecast$-4.47$-3.72$-3.72$-2.25$-1.66$-1.08$-0.49$0.04
High Forecast$-3.57$-3.66$-3.70$-2.09$-1.50$-0.64$-0.48$0.04
Low Forecast$-5.36$-3.76$-3.73$-2.35$-1.84$-1.85$-0.49$0.04
Surprise %-9.62%-3.23%-3.23%-42.22%----

Revenue Forecast

$100M $230M $360M $490M $620M $750M Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$203.56M$245.11M$312.97M$376.57M----
Avg Forecast$179.37M$241.58M$310.91M$373.27M$438.47M$522.91M$605.50M$708.05M
High Forecast$215.25M$242.01M$311.41M$375.62M$440.20M$524.65M$610.70M$714.14M
Low Forecast$143.50M$240.00M$310.12M$372.11M$434.79M$521.17M$597.70M$698.93M
Surprise %13.49%1.46%0.66%0.88%----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Sep 22 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 22Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-217.86M$-204.62M$-208.73M$-77.67M----
Avg Forecast$-214.13M$-205.80M$-215.37M$-128.91M$-96.84M$-80.93M$-28.14M$2.32M
High Forecast$-171.31M$-164.64M$-214.51M$-121.43M$-86.98M$-37.20M$-27.67M$2.35M
Low Forecast$-256.96M$-246.96M$-216.24M$-136.39M$-106.70M$-107.50M$-28.45M$2.28M
Surprise %1.74%-0.58%-3.09%-39.75%----

TWST Forecast FAQ

Is Twist Bioscience stock a buy?

Twist Bioscience stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 2 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Twist Bioscience is a favorable investment for most analysts.

What is Twist Bioscience's price target?

Twist Bioscience's price target, set by 15 Wall Street analysts, averages $153.7 over the next 12 months. The price target range spans from $89 at the low end to $215 at the high end, suggesting a potential 9.85% change from the previous closing price of $139.92.

How does Twist Bioscience stock forecast compare to its benchmarks?

Twist Bioscience's stock forecast shows a 9.85% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Twist Bioscience over the past three months?

  • October 2026: 15.38% Strong Buy, 53.85% Buy, 23.08% Hold, 7.69% Sell, 0% Strong Sell.
  • September 2026: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 18.18% Strong Buy, 63.64% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.

What is Twist Bioscience’s EPS forecast?

Twist Bioscience's average annual EPS forecast for its fiscal year ending in September 2026 is $-1.66, marking a 27.69% increase from the reported $-1.3 in 2025. Estimates for the following years are $-1.08 in 2027, $-0.49 in 2028, and $0.04 in 2029.

What is Twist Bioscience’s revenue forecast?

Twist Bioscience's average annual revenue forecast for its fiscal year ending in September 2026 is $438.47M, reflecting a 16.44% increase from the reported $376.57M in 2025. The forecast for 2027 is $522.91M, followed by $605.5M for 2028, and $708.05M for 2029.

What is Twist Bioscience’s net income forecast?

Twist Bioscience's net income forecast for the fiscal year ending in September 2026 stands at $-96.838M, representing an 24.68% increase from the reported $-77.67M in 2025. Projections indicate $-80.934M in 2027, $-28.138M in 2028, and $2.32M in 2029.